Plasminogen Activators and Plasminogen Activator Inhibitor in Portal Blood from Patients with and without Gastric Malignancy

References

• Stadnicki A, Kacperek T, Nowak A, Górka Z, Rudnicki M, Lampe P. Modulatory effect of the gastrointestinal tract (gut) on fibrinolysis and fibrinogen derivatives. Scand J Gastroenterol 1987; 22: 539–42
   PubMed Web of Science ®Google Scholar
• Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139–266
   PubMed Web of Science ®Google Scholar
• Blasi F, Vassalli JD, Danø K. Urokinase-type plasminogen activator: Proenzyme, receptor, and inhibitors. J Cell Biol 1987; 104: 801–4
   PubMed Web of Science ®Google Scholar
• Binder BR. Influence of urokinase on cell proliferation and invasion. Blood Coagul Fibrinol 1990; 1: 717–20
   PubMedGoogle Scholar
• Duffy MJ. Plasminogen activators and cancer. Blood Coagul Fibrinol 1990; 1: 681–7
   PubMedGoogle Scholar
• Huber K, Kirchheimer JC, Korninger C, Binder BR. Hepatic synthesis and clearance of components of the fibrinolytic system in healthy volunteers and in patients with different stages of liver cirrhosis. Thromb Res 1991; 62: 491–500
   PubMed Web of Science ®Google Scholar
• Leebek FWG, Kluft C, Knot EAR, De Maat MPM, Paul Wilson JH. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology 1991; 101: 1382–90
   PubMed Web of Science ®Google Scholar
• Violi F, Ferro D, Basili S, Quintarelli C, Musca A, Cordova C. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. Hepatology 1993; 17: 78–83
   PubMed Web of Science ®Google Scholar
• Takahashi H, Tatewaki W, Wada K, Yoshikawa A, Shibata A. Thrombin and plasmin generation in patients with liver disease. Am J Hematol 1989; 32: 30–5
   PubMed Web of Science ®Google Scholar
• Tran-Thang C, Fasel-Felley J, Pralong G, Hofstetter JR, Bachmann F, Kruithof EKO. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis. Thromb Haemost 1989; 62: 651–3
   PubMed Web of Science ®Google Scholar
• Lasierra J, Aza MJ, Viladés E, Poblet S, Barrao F, Bayon E. Tissue plasminogen activator and plasminogen activator inhibitor in patients with liver cirrhosis. Fibrinolysis 1991; 5: 117–20
   Google Scholar
• Lasierra J, Barrao F, Ceña G, Aza MJ, Morandeira MJ, Barrao ME. Changes of the fibrinolytic system in liver dysfunction: role of portal hypertension. Thromb Res 1992; 67: 15–21
   PubMed Web of Science ®Google Scholar
• Emeis JJ, Van Den Hoogen CM, Jense D. Hepatic clearance of tissue-type plasminogen activator in rats. Thromb Haemost 1985; 54: 661–4
   PubMed Web of Science ®Google Scholar
• Fuchs HE, Berger H, Pizzo SV. Catabolism of human tissue plasminogen activator in mice. Blood 1985; 65: 539–44
   PubMed Web of Science ®Google Scholar
• Nilsson S, Einarsson M, Ekvärn S, Häggroth L, Mattsson C. Turnover of tissue plasminogen activator in normal and hepatectomized rabbits. Thromb Res 1985; 39: 511–21
   PubMed Web of Science ®Google Scholar
• Krause J. Catabolism of tissue-type plasminogen activator (t-PA), its variants, mutants and hybrids. Fibrinolysis 1988; 2: 133–42
   Google Scholar
• Brommer EJP, Derkx FHM, Schalekamp MADH, Dooijewaard G. V. D., Klaauw MM. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man. Thromb Haemost 1988; 59: 404–11
   PubMed Web of Science ®Google Scholar
• Nilsson T, Wallén P, Mellbring G. In vivo metabolism of human tissue-type plasminogen activator. Scand J Haematol 1984; 33: 49–53
   PubMedGoogle Scholar
• Åstedt B, Holmberg L, Lecander I, Thorell J. Radioimmuno-assay of urokinase for quantification of plasminogen activators released in ovarian tumour cultures. Eur J Cancer 1981; 17: 239–44
   PubMed Web of Science ®Google Scholar
• Markus G, Camiolo SM, Kohga S, Madeja JM, Mittelman A. Plasminogen activator secretion of human tumors in short-term organ culture including a comparison of primary and metastatic colon tumors. Cancer Res 1983; 43: 5517–25
   PubMed Web of Science ®Google Scholar
• Camiolo SM, Markus G, Englander LS, Siuta MR, Hobika GH, Kohga S. Plasminogen activator content and secretion in explants of neoplastic and benign human prostate tissues. Cancer Res 1984; 44: 311–8
   PubMed Web of Science ®Google Scholar
• Pyke C, Kristensen P, Ralfkiær E, Grøndahl-Hansen J, Eriksen J, Blasi F. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991; 138: 1059–67
   PubMed Web of Science ®Google Scholar
• Grøndahl-Hansen J, Bach F, Munkholm-Larsen P. Tissue-type plasminogen activator in plasma from breast cancer patients determined by enzyme-linked immunosorbent assay. Br J Cancer 1990; 61: 412–4
   PubMed Web of Science ®Google Scholar
• Kirchheimer JC, Kölbl H, Tatra G, Binder BR. Relationship between plasma levels of components of the fibrinolytic system and acute-phase reactants in patients with uterine malignancies. Eur J Clin Invest 1990; 20: 79–84
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Cugno M, Bottasso B, Marongiu F, Maniezzo M, Vaglini M. Changes in fibrinolysis in patients with localized tumors. Eur J Cancer 1990; 26: 83–7
   PubMed Web of Science ®Google Scholar
• Kirchheimer JC, Huber K, Wagner O, Binder BR. Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas. Br J Haematol 1987; 66: 85–9
   PubMed Web of Science ®Google Scholar
• Koelbl H, Kirchheimer JC, Tatra G, Christ G, Binder BR. Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer. Obstet Gynecol 1988; 72: 252–6
   PubMed Web of Science ®Google Scholar
• Grøndahl-Hansen J, Agerlin N, Munkholm-Larsen P, Bach F, Nielsen LS, Dombemowsky P. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J Lab Clin Med 1988; 111: 42–51
   PubMed Web of Science ®Google Scholar
• Åstedt B. Immunological detection of tumour plasminogen activator in vitro and in vivo. Biological markers of neoplasia: Basic and applied aspects, RW Ruddon. Elsevier, New York 1978; 481–9
   Google Scholar
• Rahr HB, Sørensen JV, Larsen JF, Svendsen Jensen F, Bredahl C. Markers of coagulation and fibrinolysis in portal blood from patients with and without gastric malignancy. Scand J Gastroenterol 1994; 29: 516–21
   PubMed Web of Science ®Google Scholar
• Lucore CL, Sobel BE. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation 1988; 77: 660–9
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Kobayashi A, Yamazaki N, Sugawara Y, Takada Y, Takada A. Relationship between age and plasma t-PA, PA-inhibitor, and PA activity. Thromb Res 1987; 46: 625–33
   PubMed Web of Science ®Google Scholar
• Aillaud MF, Pignol F, Alessi MC, Harle JR, Escande M, Mongin M. Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor, factor VIII:C and in erythrocyte sedimentation rate with age. Thromb Haemost 1986; 55: 330–2
   PubMed Web of Science ®Google Scholar
• Sundell IB, Nilsson TK, Rånby M, Hallmans G, Hellsten G. Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Norsjö, Sweden. J Clin Epidemiol 1989; 42: 719–23
   PubMed Web of Science ®Google Scholar
• Eriksson M, Saldeen T, Wallin R. Effect of dextran on plasma tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor (PAI-1) during surgery (abstract). Thromb Haemost 1989; 62: 394
   Google Scholar
• Flordal PA, Svensson J, Ljungström KG. Effects of desmopressin and dextran on coagulation and fibrinolysis in healthy volunteers. Thromb Res 1991; 62: 355–64
   PubMed Web of Science ®Google Scholar
• Johnson EJ, Hariman H, Hampton KK, Grant PJ, Davies JA, Prentice CRM. Fibrinolysis during major abdominal surgery. Fibrinolysis 1990; 4: 147–51
   Google Scholar
• Kirchheimer JC, Binder BR, Pflueger H, Hienert G. Does plasma urokinase antigen reflect tumor urokinase in prostatic carcinoma. Thromb Haemost 1985; 54: 729
   PubMed Web of Science ®Google Scholar
• Kirchheimer JC, Pflüger H, Hienert G, Binder BR. Increased urokinase activity to antigen ratio in human renal-cell carcinoma. Int J Cancer 1985; 35: 737–41
   PubMed Web of Science ®Google Scholar
• Mellbring G, Dahlgren S, Wiman B. Plasma fibrinolytic activity in patients undergoing major abdominal surgery. Acta Chir Scand 1985; 151: 109–14
   PubMedGoogle Scholar